The company AstraZeneca reported the data of a research that shows that the drug Enhertu helps patients with one type of breast cancer live longer.
Enhertu increased survival rates in breast cancer patients in incurable stages. This marks the first time that such therapy has been shown to have benefits for patients with this form of breast cancer, AstraZeneca said.
The results "could reshape the way breast cancer is classified and treated," Susan Galbraith, executive vice president of oncology research and development, wrote in the statement.
Treatment with Enhertu showed a significant improvement in survival without further development of cancer - how long a patient can live without disease exacerbation - as well as overall survival, the company said.
The data will be presented at an upcoming medical meeting and will be provided to global health authorities.
Recommended articles about cancer:
- World Cancer Day: What you need to know, today more than ever
- Scientists are creating a revolutionary test to detect four types of cancer in women
- 5 women show what they do NOT want men to tell them about breast cancer
- What is Paget's disease of the breast
- What are the warning signs of breast cancer in both men and women
